Search
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalDue to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously. … SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway.
TD101
go.drugbank.com/drugs/DB06596InvestigationalTD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita
Mediator of RNA polymerase II transcription subunit 1
go.drugbank.com/bio_entities/BE0004382TargetHumansComponent of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the ...
Synonyms: Thyroid receptor-interacting protein 2, Peroxisome proliferator-activated receptor-binding proteinAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skele...
FAV-201
go.drugbank.com/drugs/DB06130ExperimentalFAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
CAN-106
go.drugbank.com/drugs/DB18389InvestigationalCAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
rGLP-1
go.drugbank.com/drugs/DB05433ExperimentalrGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.
Pafuramidine
go.drugbank.com/drugs/DB06532InvestigationalPafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.
Trapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
Bioymifi
go.drugbank.com/drugs/DB17493ExperimentalUpon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.